Is GH Research PLC (GHRS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 15.1% / 30% | 0.2% / 30% | N/A | ✓ HALAL |
| DJIM | 0.1% / 33% | 15.1% / 33% | 0.2% / 33% | N/A | ✓ HALAL |
| MSCI | 0.3% / 33% | 79.3% / 33% | 0.9% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 15.1% / 33% | 0.2% / 33% | N/A | ✓ HALAL |
| FTSE | 0.3% / 33% | 79.3% / 33% | 0.9% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -21.0% | |
| Return on Assets (ROA) | -15.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$44M |
| Free Cash Flow | -$44M |
| Total Debt | $512,000 |
| Debt-to-Equity | 0.2 |
| Current Ratio | 34.1 |
| Total Assets | $288M |
Price & Trading
| Last Close | $14.09 |
| 50-Day MA | $15.40 |
| 200-Day MA | $14.19 |
| Avg Volume | 375K |
| Beta | 1.0 |
|
52-Week Range
$7.98
| |
About GH Research PLC (GHRS)
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is GH Research PLC (GHRS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), GH Research PLC is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is GH Research PLC's debt ratio?
GH Research PLC's debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.3%.
What are GH Research PLC's key financial metrics?
GH Research PLC has a market capitalization of $816M. Return on equity stands at -21.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.